Synergistic effects of bis(3-methylsulfonyloxypropyl)-amine toluenesulfonate (864-T) with 6-mercaptopurine and other antitumor agents.
D000477:Alkylating Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002865:Chromomycins / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004357:Drug Synergism; D005472:Fluorouracil / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000627:therapeutic use; D008698:Mesylates / Q000008:administration & dosage* / Q000627:therapeutic use; D051379:Mice; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D012517:Sarcoma, Yoshida / Q000188:drug therapy; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D002865:Chromomycins; D008698:Mesylates; D008937:Mitomycins; D009588:Nitrogen Mustard Compounds; D014105:Tosyl Compounds; D003561:Cytarabine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D005472:Fluorouracil